Patients Empowered With Digital Scripts: ScalaMed

NCT03479034 | Withdrawn

• 1 other identifier: SCALA001
• Study Type: observational
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

A prospective qualitative and quantitative controlled study, exploring the impact of patient centred digital prescriptions on health, in patients with chronic health conditions.

Conditions

Technology

Keywords

digital; prescription; Application

Outcome Measures

Primary Outcomes (1)

• Patient preference

  Primary outcome is the change from baseline in patient preference for ScalaMed over previous prescription management tools after 3-months, determined through a questionnaire using a 4 point Likert scale. 9\) I prefer Scalamed to my previous system of managing prescriptions 1. Strongly agree 2. Somewhat agree 3. somewhat disagree 4. strongly disagree

  6 months

Secondary Outcomes (7)

• Clinician prefence

  3 months

• Prescriber satisfaction

  6 months

• Clinical Implications

  6 months

• Patient measures

  6 months

• Digital sharing

  6 months

Study Arms (1)

Group 1

* Ages 18-85 * Cognitively able to understand instructions and care for themselves * Lives in the community (not institutionalised) * Owner of a smartphone and able to use Apps * On 3 or more chronic prescription medications * Has had experience with prescriptions in Australia for at least 1 year * Current patient attending Holdsworth House Medical Practice Willing to use the ScalaMed ePrescription application

Other: ScalaMed ePrescription application

Interventions

ScalaMed ePrescription application OTHER

Mobile phone application (Android and Apple) for storing electronic prescriptions

Group 1

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients of Holdsworth House Medical Practice

You may qualify if:

• Ages 18-85
• Cognitively able to understand instructions and care for themselves
• Lives in the community (not institutionalised)
• Owner of a smartphone and able to use Apps
• On 3 or more chronic prescription medications
• Informed consent as documented by signature (Appendix Informed Consent Form)
• Has had experience with prescriptions in Australia for at least 1 year
• For the clinicians - any clinician who is using the ScalaMed prescription system in the Holdsworth House
• For pharmacists - who are utilising the ScalaMed system in one of the four clinics

You may not qualify if:

• Known or suspected non-compliance, drug or alcohol abuse
• Inability to follow the procedures of the study due to language problems, psychological disorders, dementia of the participant
• Previous enrolment into the current study

Sponsors & Collaborators

• Holdsworth House Medical Practice: lead
• ScalaMed: collaborator

Study Officials

• Tal Rapke, Dr

  ScalaMed

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 21, 2018
• First Posted: March 27, 2018
• Study Start: January 1, 2019
• Primary Completion: July 1, 2019
• Study Completion: October 1, 2019
• Last Updated: November 12, 2019

Record last verified: 2019-11

Data Sharing

• IPD Sharing: Will not share